

S1 Table. Prognostic significance of CDKs families

	ZS-MRCC cohort			JAVELIN Renal 101 cohort TKI+IO subgroup		
	p-value	Hazard ratio	95% CI	p-value	Hazard ratio	95% CI
CDK1	0.107	1.85	0.86-4.04	0.125	1.28	0.93-1.75
CDK2	0.602	1.22	0.57-2.61	0.811	1.04	0.76-1.42
CDK3	0.850	0.93	0.44-2.01	0.003	1.60	1.17-2.20
CDK4	0.500	1.29	0.61-2.77	0.176	1.24	0.91-1.70
CDK5	0.014	3.20	1.20-8.60	0.040	1.43	1.01-2.03
CDK6	0.010	2.63	1.23-5.98	0.417	1.14	0.83-1.56
CDK7	0.217	1.60	0.75-3.45	0.244	0.83	0.61-1.14
CDK8	0.109	0.54	0.25-1.16	0.552	0.91	0.66-1.24
CDK9	0.074	0.51	0.22-1.09	0.731	1.06	0.77-1.45
CDK10	0.978	1.01	0.48-2.16	0.199	0.82	0.59-1.11
CDK11A	0.154	1.72	0.81-3.72	0.950	0.99	0.72-1.35
CDK11B	0.061	2.03	0.95-4.54	0.342	0.86	0.63-1.18
CDK12	0.747	0.88	0.41-1.88	0.775	1.05	0.77-1.43
CDK13	0.844	0.93	0.43-1.98	0.334	1.17	0.85-1.60
CDK14	0.319	1.46	0.69-3.15	0.866	1.06	0.56-2.00
CDK15	0.323	0.69	0.32-1.46	0.536	1.10	0.81-1.51
CDK16	0.799	0.91	0.42-1.92	0.986	1.00	0.73-1.37
CDK17	0.547	1.26	0.59-2.70	0.297	1.18	0.86-1.62
CDK18	0.902	1.05	0.49-2.24	0.464	1.12	0.82-1.54
CDK19	0.084	0.52	0.23-1.12	0.959	1.01	0.74-1.38
CDK20	0.178	0.59	0.27-1.29	0.593	0.92	0.67-1.26
CDKL1	0.011	0.37	0.16-0.82	0.617	0.92	0.67-1.26
CDKL2	0.798	0.91	0.42-1.94	0.616	1.08	0.79-1.48
CDKL3	0.718	1.15	0.54-2.45	0.986	1.00	0.72-1.40
CDKL4	0.601	1.22	0.57-2.61	0.024	1.43	1.05-1.97
CDKL5	0.252	0.65	0.30-1.38	0.125	1.28	0.93-1.75

CDK, cyclin-dependent kinase; CI, confidence interval; IO, immunotherapy; TKI, tyrosine kinase inhibitor; ZS-MRCC, Zhongshan Metastatic Renal Cell Carcinoma.